JP2017531687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531687A5 JP2017531687A5 JP2017522502A JP2017522502A JP2017531687A5 JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5 JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- modified human
- modified
- immune system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 123
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 78
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 65
- 210000000987 immune system Anatomy 0.000 claims description 60
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 claims description 51
- 102000044493 human CDCA4 Human genes 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 37
- 102000025171 antigen binding proteins Human genes 0.000 claims description 27
- 108091000831 antigen binding proteins Proteins 0.000 claims description 27
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 25
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 25
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 25
- 239000012636 effector Substances 0.000 claims description 23
- 230000003834 intracellular effect Effects 0.000 claims description 21
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- -1 CD79b Proteins 0.000 claims description 18
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 16
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 16
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 16
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 102100027207 CD27 antigen Human genes 0.000 claims description 13
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 102100027271 40S ribosomal protein SA Human genes 0.000 claims description 8
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 230000001400 myeloablative effect Effects 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 102100035893 CD151 antigen Human genes 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 102100027221 CD81 antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 4
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 4
- 101710181403 Frizzled Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 4
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 4
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 4
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims description 4
- 101000997535 Homo sapiens Growth hormone-releasing hormone receptor Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 4
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 4
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims description 4
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims description 4
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 4
- 108010071083 Patched-2 Receptor Proteins 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 102100028680 Protein patched homolog 1 Human genes 0.000 claims description 4
- 102100036894 Protein patched homolog 2 Human genes 0.000 claims description 4
- 101150097792 Robo1 gene Proteins 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 4
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 4
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 4
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 4
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 4
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 2
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 2
- 229960000951 mycophenolic acid Drugs 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000002918 testicular germ cell tumor Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 claims 4
- 101100364669 Caenorhabditis elegans lin-18 gene Proteins 0.000 claims 4
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims 4
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims 4
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 4
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 claims 4
- 101100364671 Mus musculus Ryk gene Proteins 0.000 claims 4
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims 4
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims 4
- 102100025247 Neurogenic locus notch homolog protein 3 Human genes 0.000 claims 4
- 102100025254 Neurogenic locus notch homolog protein 4 Human genes 0.000 claims 4
- 108010029755 Notch1 Receptor Proteins 0.000 claims 4
- 108010029751 Notch2 Receptor Proteins 0.000 claims 4
- 108010029756 Notch3 Receptor Proteins 0.000 claims 4
- 108010029741 Notch4 Receptor Proteins 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 2
- 101150028321 Lck gene Proteins 0.000 claims 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 210000003515 double negative t cell Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462069168P | 2014-10-27 | 2014-10-27 | |
| US62/069,168 | 2014-10-27 | ||
| PCT/US2015/057652 WO2016069647A1 (en) | 2014-10-27 | 2015-10-27 | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531687A JP2017531687A (ja) | 2017-10-26 |
| JP2017531687A5 true JP2017531687A5 (enExample) | 2018-12-06 |
| JP7005346B2 JP7005346B2 (ja) | 2022-02-04 |
Family
ID=54545485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522502A Active JP7005346B2 (ja) | 2014-10-27 | 2015-10-27 | 養子細胞免疫療法の有効性を増強させるための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10828352B2 (enExample) |
| EP (1) | EP3212223B1 (enExample) |
| JP (1) | JP7005346B2 (enExample) |
| KR (1) | KR102357004B1 (enExample) |
| CN (1) | CN107106611B (enExample) |
| AU (1) | AU2015339402B2 (enExample) |
| BR (2) | BR112017008710A8 (enExample) |
| CA (1) | CA2965347C (enExample) |
| ES (1) | ES2897731T3 (enExample) |
| HK (1) | HK1243631A1 (enExample) |
| MX (1) | MX389823B (enExample) |
| NZ (1) | NZ731279A (enExample) |
| RU (1) | RU2716716C2 (enExample) |
| WO (1) | WO2016069647A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2753351B1 (en) | 2011-09-08 | 2017-06-21 | Yeda Research and Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| WO2013151771A1 (en) | 2012-04-05 | 2013-10-10 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| RU2016143389A (ru) | 2014-04-10 | 2018-05-15 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| DK3322425T3 (da) | 2015-07-16 | 2023-06-12 | Yeda Res & Dev | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi |
| CN108135935A (zh) | 2015-07-21 | 2018-06-08 | 儿童医疗中心有限公司 | 表达pd-l1的造血干细胞及其用途 |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| AU2017210327A1 (en) | 2016-01-20 | 2018-08-09 | Nbe-Therapeutics Ag | ROR1 antibody compositions and related methods |
| EP3411408B1 (en) | 2016-02-02 | 2021-12-08 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| WO2017192924A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| IL263110B (en) * | 2016-05-20 | 2022-07-01 | Lilly Co Eli | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| CN106199005B (zh) * | 2016-07-26 | 2019-02-01 | 浙江大学 | 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法 |
| CA3045355A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| US20190350978A1 (en) | 2016-12-05 | 2019-11-21 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| WO2018134824A1 (en) * | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
| CN107267555B (zh) | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| AU2018314242A1 (en) * | 2017-08-11 | 2020-02-13 | Fred Hutchinson Cancer Center | BRAF-specific TCRs and uses thereof |
| EP3684408A1 (en) * | 2017-09-19 | 2020-07-29 | Massachusetts Institute of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| CN111433354A (zh) * | 2017-09-26 | 2020-07-17 | 朗沃德大学 | 作为免疫疗法的pd1特异性嵌合抗原受体 |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| CA3082334A1 (en) * | 2017-11-20 | 2019-05-23 | Julius-Maximilians-Universitat Wurzburg | Cd19cart cells eliminate myeloma cells that express very low levels of cd19 |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| CN109810995B (zh) * | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
| CN108148137B (zh) * | 2017-12-29 | 2021-03-23 | 中国人民解放军第四军医大学 | 一种b7h4/1e10单克隆抗体及其应用 |
| EP3844266A1 (en) * | 2018-08-28 | 2021-07-07 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
| CN111544585B (zh) * | 2019-02-11 | 2024-12-27 | 北京卡替医疗技术有限公司 | 一种可助推免疫细胞在体内扩增的佐剂 |
| JP2022525781A (ja) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫細胞療法における両親媒性物質の使用およびそのための組成物 |
| US20220257794A1 (en) * | 2019-06-14 | 2022-08-18 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2021263211A2 (en) * | 2020-06-25 | 2021-12-30 | Houston Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| US20050129671A1 (en) * | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| US20090324630A1 (en) * | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| WO2012140130A1 (en) * | 2011-04-13 | 2012-10-18 | Immunicum Ab | Method for proliferation of antigen-specific t cells |
| JP6117515B2 (ja) | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | 髄膜腫治療用医薬組成物 |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
-
2015
- 2015-10-27 BR BR112017008710A patent/BR112017008710A8/pt not_active Application Discontinuation
- 2015-10-27 US US15/521,794 patent/US10828352B2/en active Active
- 2015-10-27 EP EP15795073.4A patent/EP3212223B1/en active Active
- 2015-10-27 BR BR122021000068A patent/BR122021000068A8/pt not_active Application Discontinuation
- 2015-10-27 KR KR1020177013868A patent/KR102357004B1/ko active Active
- 2015-10-27 NZ NZ731279A patent/NZ731279A/en unknown
- 2015-10-27 AU AU2015339402A patent/AU2015339402B2/en active Active
- 2015-10-27 JP JP2017522502A patent/JP7005346B2/ja active Active
- 2015-10-27 MX MX2017005344A patent/MX389823B/es unknown
- 2015-10-27 CA CA2965347A patent/CA2965347C/en active Active
- 2015-10-27 HK HK18103005.7A patent/HK1243631A1/zh unknown
- 2015-10-27 RU RU2017114174A patent/RU2716716C2/ru active
- 2015-10-27 WO PCT/US2015/057652 patent/WO2016069647A1/en not_active Ceased
- 2015-10-27 CN CN201580071144.9A patent/CN107106611B/zh active Active
- 2015-10-27 ES ES15795073T patent/ES2897731T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531687A5 (enExample) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| Johdi et al. | Colorectal cancer immunotherapy: options and strategies | |
| Baxevanis et al. | Cancer immunotherapy | |
| Kiesgen et al. | Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Wang et al. | Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| JP2022535429A (ja) | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ | |
| JP2020509767A5 (enExample) | ||
| JP7717686B2 (ja) | キメラｃｄ３融合タンパク質と抗ｃｄ３ベースの二重特異性ｔ細胞活性化エレメントの複合発現 | |
| CN111787938A (zh) | 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法 | |
| JP2015527070A5 (enExample) | ||
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| CN111247241A (zh) | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| CN108410892A (zh) | 降低由pd-l1诱导的免疫耐受性 | |
| WO2018210279A1 (zh) | Toll样受体激动剂与免疫效应细胞的联用 | |
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience | |
| Kato et al. | Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies |